FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden	
hours por rosponso:	0.5

0.5

				or	Section 30(h) of the Investment Compar	y Act of 1940					
				of Event Requir nt (Month/Day/ 2021		3. Issuer Name and Ticker or Trading Symbol <u>IsoPlexis Corp</u> [ISO]						
(Last) (First) (Middle) C/O ISOPLEXIS CORPORATION 35 NE INDUSTRIAL RD (Street) BRANFORD CT (City) (State) (Zip)		-			4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Commercial Officer			pelow) 6. In	 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 			
				Table I -	Non-Deriv	ative Securities Be	neficially Owne	ed				
1. Title of Security (Instr. 4)						2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)				4. Nature of Indirect Beneficial Ownership (Instr. 5)		
						tive Securities Bene rrants, options, con		ies)				
1. Title of Derivative Security (Instr. 4)				2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlyi Security (Instr. 4)		g Derivative	4. Conversion or Exercise	5. Ownership Form: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
				Date Exercisable	Expiration Date	Title		Amount or Number of Shares	Price of Derivative Security	(Instr. 5)		
Stock Option (right to buy)				(1)	06/09/2030	Common	Stock	28,000 ⁽¹⁾ 1.027		D		
Stock Option (right to buy)				(2)	06/09/2030	Common	Stock	52,000 ⁽²⁾ 1.0275		D		
Stock Option (right to buy)				(3)	12/14/2030	Common	Stock	20,000 ⁽³⁾	1.83	D		
Stock Option (right to buy)				(4)	06/07/2031	Common	Stock	80,000(4)	4.81	D		

Explanation of Responses:

1. Represents 28,000 performance-vesting options. Performance-vesting options are subject to vesting based upon the achievement of the 2020 revenue target of IsoPlexis Corporation, which was achieved, and a four-year time-based vesting schedule, with 25% vested on May 18, 2021 and the remainder vesting in 36 equal installments every month thereafter. 2. Represents 52,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vested on May 18, 2021 and the remainder vesting in 36 equal installments every month thereafter.

3. Represents 20,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vesting on December 15, 2021 and the remainder vesting in 36 equal installments every month thereafter. 4. Represents 80,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vesting on June 8, 2022 and the remainder vesting in 36 equal installments every month thereafter.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Shane Sevier, attorney-in-fact for 10/07/2021 Peter Siesel

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of John Strahley and Shane Sevier as the undersigned's true and lawful attorneys-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as a reporting person pursuant to Section 16 of the Securities
(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such
(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of any of such attorneys-in-fact, may I
The undersigned hereby grants to each such attorney-in-fact full power and authority to act separately and to do and perform any and every act
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this July 26, 2021.

/s/ Peter Siesel

Name: Peter Siesel